Call to Schedule Free Consultation at Over 80 Centers Worldwide!

(844) GET-STEM

Does Stem Cell Therapy Cause Tumors or Fibrosis? Understanding the Safety Profile

Written by Dr. David Greene, MD, PhD, MBA on June 24, 2026

Table of Contents

As regenerative medicine continues to evolve, patients researching stem cell therapies frequently encounter safety questions. A primary concern for many is whether these advanced therapies can trigger adverse long-term effects, specifically abnormal tissue growth (tumors) or internal scarring (fibrosis).

To evaluate these risks accurately, it is essential to distinguish between the different types of stem cells used in research versus those deployed in modern clinical treatments.

The Crucial Difference: Pluripotent vs. Multipotent Stem Cells

The risk profile of a stem cell procedure depends fundamentally on the classification of the cells used. The medical community categorizes these cells based on their differentiation potential:

1. Embryonic (Pluripotent) Stem Cells

Embryonic stem cells (ESCs) are derived from blastocysts. Because they are pluripotent, they have the capacity to differentiate into any cell type in the human body. While this makes them valuable for laboratory research, it poses a significant clinical safety hazard: ESCs often lack the biological “shut-off” mechanisms that regulate replication. When introduced into a living organism, this unregulated replication can lead to the formation of benign tumors known as teratomas.

To better understand why these cells are restricted from general human applications, patients can explore the history of stem cell research controversy, which details both the safety concerns and ethical dilemmas associated with tissues obtained from embryonic origins. Because of these safety boundaries, modern clinical procedures strictly avoid stem cell therapy using aborted fetuses due to the high volatility and lack of cellular control.

2. Adult and Perinatal (Multipotent) Stem Cells

In contrast, clinical regenerative medicine relies on multipotent stem cells. Reviewing the basic kinds of stem cells shows that these include Mesenchymal Stem Cells (MSCs) and Hematopoietic Stem Cells (HSCs) sourced from:

Umbilical cord tissue (perinatal)

Bone marrow (adult)

Adipose/fat tissue (adult)

Multipotent stem cells are pre-programmed to differentiate only into a limited lineage of cell types (such as bone, cartilage, or blood cells). Because their replication cycle is naturally restricted, they do not present the same inherent risk of uncontrolled proliferation or teratoma formation seen with embryonic tissue. Patients can discover more about these cell types in a comprehensive stem cell basics overview, which outlines how safely harvested tissue preserves healthy function.

Evaluating the Risks of Fibrosis and Abnormal Tissue Growth

Does Stem Cell Therapy Cause Fibrosis?

Fibrosis refers to the thickening and scarring of connective tissue, which can impair organ function. Peer-reviewed literature indicates that multipotent MSCs do not cause fibrosis. In fact, current clinical data demonstrate that MSCs exhibit anti-fibrotic properties.

During tissue injury, MSCs secrete bioactive molecules—such as cytokines and growth factors—that actively suppress chronic inflammation and downregulate the overproduction of collagen by myofibroblasts. This mechanism makes stem cell therapy a subject of intense research for treating fibrotic conditions. For instance, targeted studies illustrate that stem cell therapy has the potential to help patients with kidney failure, where progressive internal scarring typically destroys vital renal structures over time.

Can Multipotent Stem Cells Cause Tumors?

Extensive clinical trials and real-world data have shown that multipotent MSCs and HSCs do not cause tumor formation in patients. Reviewing the complete risk-benefit analysis of mesenchymal stem cell therapy affirms that their safety profile remains exceptional when delivered properly. Basic science models even suggest that perinatal tissue-derived stem cells (like those from the umbilical cord matrix) exhibit intrinsic anti-tumor properties, interacting with signaling pathways to inhibit certain cancer cell lines.

However, because stem cells naturally promote tissue healing and blood vessel growth (angiogenesis), strict patient selection is critical. Responsible medical protocols dictate that stem cell therapies should not be administered to patients currently undergoing active cancer treatments.

Safety Standards in Clinical Practice

Stem Cell Type

Differentiation Potential

Tumor / Teratoma Risk

Primary Clinical Use

Embryonic (ESC)

Pluripotent (All cell types)

High Risk

Laboratory Research Only

Mesenchymal (MSC)

Multipotent (Specific lineages)

Minimal to No Documented Risk

Regenerative Therapies

Hematopoietic (HSC)

Multipotent (Blood/Immune cells)

Minimal to No Documented Risk

Cellular Therapies & Transplants

When seeking regenerative care, patients should partner with established providers that prioritize rigorous safety standards. Organizations like R3 Stem Cell maintain an exemplary safety record by utilizing exclusively multipotent, ethically sourced umbilical cord and adult stem cells. Across a global network spanning over 80 clinics and more than 29,000 completed procedures, these rigorous protocols ensure that therapies work in harmony with the body’s natural healing mechanisms without inducing abnormal tissue growth.

If you are considering regenerative treatment options, always look for providers that offer comprehensive, transparent medical consultations to evaluate your unique health status and history.

Contact Us

Evaluating the Risks of Fibrosis and Abnormal Tissue Growth

Where Do Exosomes Come From?